Simvastatin

Simvastatin has been studied in 197 papers since 1993: 38 trials and 49 observational studies in people, 58 in animals, 19 in cells, 24 reviews; 69 in the past year. It is an approved medicine. The newest story, Oct 16, 2026: “Genetic study links protein to spinal narrowing in people”.

InterventionStatinsApproved 1991

197 papers study it21 more mention it205 findingsUpdated

PubChemChEBIMeSH

7 new papers in 30 daysSee all 215 papers on simvastatin

At a glance

Simvastatin extends lifespan in a fly study but shows no clear lifespan effect in mouse studies. Independent labs report lower coenzyme Q10 and opposing oxidative-stress changes in humans; some trials show no clear coenzyme Q10 effect. Aging trials are registered; some papers declare developer ties, and across all uses, some trials are developer-sponsored and some ended over a year ago without posted results.

205 findings in 98 papers from 1993 to 2026, 5 of them since August 2026

Independent labs found the same change in cells, worms or flies, mice and people. 79 independent labs in 30 countries; 356 trials, 69 about aging, 171 with no results posted.

“Significant reductions in LDL-C levels were observed among participants from groups of NRYR, Simvastatin, and the combination of both”
Natto Red Yeast Rice Dietary Supplement Regulates Lipids Profiles: a Multicenter, Double-Placebo, Double-Blinded, Randomized Controlled TrialAHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4368299

17 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 79 independent labs in 30 countries
  • 17 findings against
  • 356 trials, 69 about aging, 171 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 10 of 199 findings with company ties
  • 79 of 356 trials sponsored by its developers
  • Human trial38
  • Humans49
  • Animals55
  • Model organisms2
  • Cells18
  • In silico4

19 studies gave simvastatin to people and measured what changed.

What changedDesignPeopleSource

up: Improves vertical alveolar bone height preservation-1.58 mm, 95% CI: -3.26 to -0.73 mm

Randomized trial12 weeks40 people18–45 yearsPatients undergoing surgical extraction of impacted mandibular third molarsClinical oral investigations, Mar 25, 2026

down: Decreases peri-implant crestal bone lossp < 0.001

Randomized trial12 months24 peopleImmediate-implant casesPharmaceuticals (Basel, Switzerland), Feb 26, 2026

no change: Has no effect on pulpotomy success rate92.5% vs 96.2%

Randomized trial12 months60 peopleIn cariously exposed permanent mandibular molars with symptomatic irreversible pulpitisAustralian endodontic journal : the journal of the Australian Society of Endodontology Inc, Feb 6, 2026

no change: Has no effect on confirmed disability progressionadjusted hazard ratio 1.13 [95% CI 0.91 to 1.39], p=0.26

Randomized trialup to 4.5 years964 peopleBoth18-65 yearsMidlife adults; secondary progressive multiple sclerosisLancet (London, England), Oct 1, 2025

up: Increases MDS-UPDRS part III score1.52 points (2-sided 80% CI -0.77 to 3.80)

Randomized trial24 months178 peopleBoth40 to 90 yearsMeasured while not taking medication; placebo-controlledJAMA neurology, Nov 1, 2022

What did mouse lifespan tests of simvastatin find?

NIA ITP

The NIA Interventions Testing Program ran 2 arms in 2006; the change in median lifespan ran from −4% to +4%.

What did other lifespan studies of simvastatin find?

DrugAge

DrugAge records 4 results from 2 papers: 3 in C. elegans and 1 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

What did studies of simvastatin find?

143

Studies of simvastatin measured 143 outcomes; the most studied are inflammation (9 studies), oxidative stress and ROS signaling (7) and coenzyme Q10 (6).

Inflammation

downin mice3downin rats3downin cells1downin F. catus1+2

9 studies
  1. Simvastatin decreases inflammation in humans (carotid atherosclerotic plaque).

    “TNF-α, IL-6, and hs-CRP levels in the observation group decreased after treatment compared with those before treatment and those in the control group.”

    Human trialcarotid atherosclerotic plaquetablet20 mg/dayn = 65

    Efficacy of simvastatin on carotid atherosclerotic plaque and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients

    Experimental and therapeutic medicine

  2. Simvastatin decreases inflammation in hPDLSCs.

    “Both SIM concentrations (0.1 and 1 μM) significantly reduced the basal expression of these inflammatory cytokines compared to that in the control group (p < 0.001).”

    Cellsin hPDLSCs0.1 and 1 μM12 monthsmalesn = 24

    Simvastatin Enhances Stem Cell Osteogenesis and Reduces Peri-Implant Bone Loss: An In Vitro and a Randomized Clinical Study

    Pharmaceuticals (Basel, Switzerland)

  3. Simvastatin decreases inflammation in vitro.

    “Both SIM concentrations (0.1 μM and 1 μM) significantly reduced basal pro-inflammatory cytokine expression (TNF-α and IL-6).”

    Cellsin vitroperiodontal ligament stem cells0.1 μM and 1 μM

    Simvastatin Enhances Stem Cell Osteogenesis and Reduces Peri-Implant Bone Loss: An In Vitro and a Randomized Clinical Study

    Pharmaceuticals (Basel, Switzerland)

  4. Simvastatin decreases inflammation in OAPS mouse model.

    “Simvastatin attenuated maternal vascular inflammation and rectified uteromaternal hemodynamic aberrations in mice.”

    Animalsin OAPS mouse model

    Simvastatin Restores Uteroplacental Hemodynamics and Trophoblast Function in Obstetric Antiphospholipid Syndrome in a Placenta-on-a-Chip Model

    Advanced healthcare materials

  5. Simvastatin decreases inflammation in F. catus (ovarian autotransplantation).

    “Treatment with SIM and EPO resulted in generally smaller areas of inflammation in the tissue.”

    Animalsovarian autotransplantationovary

    Simvastatin and EPO in feline ovarian grafting: Distinct effects on cell and follicle survival

    Theriogenology

  6. Simvastatin decreases inflammation in rats with chronic cerebral hypoperfusion.

    “Simvastatin administration effectively reduced lipid buildup, suppressed inflammation, and restored TJ integrity.”

    Animalswith chronic cerebral hypoperfusionbrain microvascular endothelial cells

    Simvastatin Ameliorates Lipid Metabolism-Mediated Endothelial Inflammation and Tight Junction Impairment in Chronic Cerebral Hypoperfusion

    Neuromolecular medicine

  7. Simvastatin decreases inflammation in mice (maternal separation).

    “Simvastatin abridged the hippocampal nitrite content and neuroinflammatory response.”

    Animalsmaternal separationhippocampus2.5, 5 and 10 mg/kg2 weeks

    Modulation of Neuroinflammation and Nitrite Imbalance in the Hippocampus by Simvastatin: Therapeutic Potential in Maternal Separation-Induced Autism Spectrum Disorder

    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience

  8. Simvastatin decreases inflammation in ConA-induced AIH model.

    “significantly reducing the secretion of crucial inflammatory cytokines in vivo and vitro, including IL-17A, IL-6, IFN-γ, and TNF-α.”

    Animalsin ConA-induced AIH model

    Simvastatin Alleviates ConA-Induced Autoimmune Hepatitis by Inhibiting CD4⁺ T Cell Activation via Calcium-NFATC3 Pathway

    Inflammation

  9. Simvastatin decreases inflammation in rats (AlCl3-induced rat model; free and nanocarrier forms).

    “They showed strong antioxidant and anti-inflammatory effects by decreasing MDA, TNF-α, IL-1β and increased GSH.”

    AnimalsAlCl3-induced rat model; free and nanocarrier forms10 mg/kg28 daysmales

    Nanocarrier-enhanced simvastatin modulates AMPK-ULK1 pathway and oxidative stress in Alzheimer's disease model

    European journal of pharmacology

  10. Simvastatin decreases inflammation in rats with acute pulmonary embolism.

    “APE rats treated with simvastatin led to a significant opposite trend of the above indexes.”

    Animalsin rats with acute pulmonary embolism10 mg/kg14 daysn = 24

    Effect of simvastatin on the SIRT2/NF-κB pathway in rats with acute pulmonary embolism

    Pharmaceutical biology

More on Inflammation

Oxidative stress and ROS signaling

downin rats3upin C. albicans cells1no changein humans1downin humans1+1

7 studies
  1. Simvastatin showed no clear effect on oxidative stress and ROS signaling in humans.

    “Maximal ROS production was similar among groups.”

    Human trialskeletal muscle

    Statin Treatment Decreases Mitochondrial Respiration But Muscle Coenzyme Q10 Levels Are Unaltered: The LIFESTAT Study

    The Journal of clinical endocrinology and metabolism

  2. Simvastatin decreases oxidative stress and ROS signaling in humans (-19% for MDA and All/UA ratio; -26% and -28% with ezetimibe/simvastatin 10/40 mg/day).

    “A significant decrease of both MDA and All/UA ratio was observed during therapy for all patients”

    Human trialMDA and allantoin/uric acid ratio as markers; larger fall with ezetimibe/simvastatin 10/40 mg/day12 months

    Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy

    Amino acids

  3. Simvastatin increases oxidative stress and ROS signaling in humans (coronary heart disease with dyslipidemia) (25% and 29%).

    “at the same time, its use led to a significant increase in the level of primary and secondary lipid peroxidation (LP) products (25% and 29%, respectively)”

    Human trialcoronary heart disease with dyslipidemia20 mg a dayone monthn = 26

    Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia

    Klinicheskaia meditsina

  4. Simvastatin increases oxidative stress and ROS signaling in C. albicans cells (Strain MTCC 854) (4-fold increase).

    “ROS generation assay revealed an 18-fold increase in oxidative stress with Atorvastatin, while Simvastatin showed only a 4-fold increase.”

    CellsStrain MTCC 854

    Repurposing statins as potential antifungal agents for Candida albicans: in-vitro and in-silico approach

    Future microbiology

  5. Simvastatin decreases oxidative stress and ROS signaling in rats (AlCl3-induced rat model; free and nanocarrier forms).

    “They showed strong antioxidant and anti-inflammatory effects by decreasing MDA, TNF-α, IL-1β and increased GSH.”

    AnimalsAlCl3-induced rat model; free and nanocarrier forms10 mg/kg28 daysmales

    Nanocarrier-enhanced simvastatin modulates AMPK-ULK1 pathway and oxidative stress in Alzheimer's disease model

    European journal of pharmacology

  6. Simvastatin decreases oxidative stress and ROS signaling in rats (surgically inserted titanium implants).

    “Additionally, levels of oxidative stress and inflammatory factors decreased with both treatments when compared to the Control group alone (all, P < 0.05).”

    Animalssurgically inserted titanium implants12 weeksmales

    Combination treatment with whole body vibration and simvastatin improves the early osseointegration in aged rats

    Bone reports

  7. Simvastatin decreases oxidative stress and ROS signaling in rats (streptozotocin-induced diabetes).

    “Simvastatin diminished the changes in oxidative stress markers and succeeded to ameliorate the diabetic induced cerebellar changes.”

    Animalsstreptozotocin-induced diabetescerebellum10 mg/kg once daily

    The neuroprotective effect of simvastatin on the cerebellum of experimentally-induced diabetic rats through klotho upregulation: An immunohistochemical study

    Journal of chemical neuroanatomy

More on Oxidative stress and ROS signaling

Coenzyme Q10

downin humans4no changein humans2−40% reduction

6 studies
  1. Simvastatin decreases coenzyme Q10 in humans.

    “Simvastatin treatment decreases plasma concentrations of total CoQ10, but this can be alleviated by simultaneous supplementation with CoQ10.”

    Human trial40 mg/day

    The effect of 8 weeks of physical training on muscle performance and maximal fat oxidation rates in patients treated with simvastatin and coenzyme Q10 supplementation

    The Journal of physiology

  2. Simvastatin showed no clear effect on coenzyme Q10 in patients receiving simvastatin.

    “Intramuscular CoQ10 concentration was comparable among groups.”

    Human trialin patients receiving simvastatinskeletal muscle

    Statin Treatment Decreases Mitochondrial Respiration But Muscle Coenzyme Q10 Levels Are Unaltered: The LIFESTAT Study

    The Journal of clinical endocrinology and metabolism

  3. Simvastatin showed no clear effect on coenzyme Q10 in humans.

    “Randomization from the initial trial had no effect on CoQ10 level.”

    Human trialmaximum of seven days or until hospital dischargen = 14

    Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock

    Critical care (London, England)

  4. Simvastatin showed no clear effect on coenzyme Q10 in patients with septic shock (P = 0.13).

    “Statin therapy had no effect on plasma CoQ10 levels over time (P = 0.13).”

    Human trialin patients with septic shockn = 14

    Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock

    Critical care (London, England)

  5. Simvastatin decreases coenzyme Q10 in humans (0.82 ± 0.18 mg/L vs baseline 0.99 ± 0.30 mg/L (p = 0.0002)).

    “significantly decreased in the simvastatin and combination groups (0.82 +/- 0.18 mg/L, p = 0.0002 and 0.7 +/- 0.22 mg/L, p < 0.0001, respectively)”

    Human trial40 mg/day14 daysmales

    Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial

    Drug safety

  6. Simvastatin decreases coenzyme Q10 in hypercholesterolemic outpatients (from 1.08 mg/dl to 0.80 mg/dl).

    “In the S group, there was a marked decrease in TC and LDL-C (from 290.3 mg/dl to 228.7 mg/dl for TC and from 228.7 mg/dl to 167.6 mg/dl for LDL-C) and in plasma CoQ10 levels from 1.08 mg/dl to 0.80 mg/dl.”

    Human trialin hypercholesterolemic outpatientsplasma20 mg6 monthsn = 34

    Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors

    Molecular aspects of medicine

  7. Simvastatin decreases coenzyme Q10 in humans (hypercholesterolemia; compared with placebo) (About 40% reduction).

    “The same extent of reduction, compared with placebo was measured in hypercholesterolemic patients treated with pravastatin or simvastatin.”

    Human trialhypercholesterolemia; compared with placeboplasma20 mg/day3 monthsn = 30

    Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study

    Journal of clinical pharmacology

More on Coenzyme Q10

Lifespan

no changein mice3downin flies1upin flies1

5 studies
  1. Simvastatin shortens lifespan in flies (co-treatment with clozapine, compared with clozapine alone).

    “Clozapine alone significantly extended median survival, an effect attenuated by simvastatin co-treatment.”

    Model organismsco-treatment with clozapine, compared with clozapine alone

    Co-administration of simvastatin mitigates clozapine-induced lifespan extension and mitochondrial functional recovery in Drosophila melanogaster

    bioRxivPreprint

  2. Simvastatin showed no clear effect on lifespan in SOD1G93A transgenic mouse model of ALS.

    “Although there were no significant differences in survival rates, body weight, pole climbing, and suspension test performance, or neurological deficit scores between the SOD1G93A + simvastatin and SOD1G93A + PBS groups”

    Animalsin SOD1G93A transgenic mouse model of ALS

    Therapeutic potential of simvastatin in ALS: Enhanced axonal integrity and motor neuron survival through Apoa4 and Alb modulation

    Biomolecules & biomedicine

  3. Simvastatin showed no clear effect on lifespan in mice.

    “In contrast, simvastatin, ramipril, or candesartan monotherapy was ineffective.”

    Animalsin foodmales

    Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice

    Age (Dordrecht, Netherlands)

  4. Simvastatin extends lifespan in Drosophila melanogaster.

    “simvastatin significantly increased the mean and maximum lifespan of Drosophila melanogaster (Drosophila)”

    Model organismsin Drosophila melanogaster

    Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation

    PloS one

  5. Simvastatin showed no clear effect on lifespan in mice.

    “Resveratrol (at 300 and 1200 ppm food) and simvastatin (12 and 120 ppm) did not have significant effects on survival in male or female mice.”

    Animals12 and 120 ppm in foodmale and females

    Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice

    The journals of gerontology. Series A, Biological sciences and medical sciences

Angiogenesis

no changein F. catus1upin human cells1downin human cells1

3 studies
  1. Simvastatin activates angiogenesis in human cells (SHED-HUVEC co-culture).

    “Simvastatin also elevated the expression of angiogenic regulatory factors in SHED, promoting more extensive reticular structure formation by HUVEC through paracrine interactions between SHED and HUVEC.”

    CellsSHED-HUVEC co-culture

    Coordinated effect of simvastatin-induced osteogenesis and angiogenesis mediated by Wnt/β-catenin signaling pathway on vascularized bone tissue formation

    Journal of translational medicine

  2. Simvastatin inhibits angiogenesis in human cells (high concentrations, alone or combined with alendronate) (near abolishment).

    “The same exposure induced near abolishment of secreted levels of cytokines affecting angiogenesis, such as VEGF, IL-6, IL-8, and MCP-1”

    Cellshigh concentrations, alone or combined with alendronategingival fibroblasts and osteoblasts

    Bisphosphonate and statin: adverse effects of co-medication on wound healing in in vitro models of periodontal tissues

    Acta odontologica Scandinavica

  3. Simvastatin showed no clear effect on angiogenesis in F. catus (ovarian autotransplantation).

    “There was no significant difference in the vascularization area among the groups on any post-transplant day.”

    Animalsovarian autotransplantationovary

    Simvastatin and EPO in feline ovarian grafting: Distinct effects on cell and follicle survival

    Theriogenology

More on Angiogenesis

Stem cell differentiation

upin human cells2upin cells1

2 studies
  1. Simvastatin induces stem cell differentiation in human cells (osteogenic differentiation).

    “0.1 μM simvastatin significantly upregulated osteogenic gene expression in SHED, accompanied by increased ALP activity and matrix mineralization.”

    Cellsosteogenic differentiationstem cells from human exfoliated deciduous teeth0.1 μM

    Coordinated effect of simvastatin-induced osteogenesis and angiogenesis mediated by Wnt/β-catenin signaling pathway on vascularized bone tissue formation

    Journal of translational medicine

  2. Simvastatin increases stem cell differentiation in osteogenic differentiation of hPDLSCs.

    “Quantitative analysis revealed significantly greater calcium deposition in the 0.1 μM SIM group (p < 0.0001), indicating enhanced osteogenic differentiation.”

    Cellsin osteogenic differentiation of hPDLSCs0.1 μM12 monthsmalesn = 24

    Simvastatin Enhances Stem Cell Osteogenesis and Reduces Peri-Implant Bone Loss: An In Vitro and a Randomized Clinical Study

    Pharmaceuticals (Basel, Switzerland)

  3. Simvastatin increases stem cell differentiation in vitro.

    “Lower SIM concentrations (0.1 μM) enhanced osteogenic differentiation, as evidenced by increased mineralization, alkaline phosphatase activity, and expression of osteogenic markers (RUNX2 and osteocalcin)”

    Cellsin vitroperiodontal ligament stem cells0.1 μM

    Simvastatin Enhances Stem Cell Osteogenesis and Reduces Peri-Implant Bone Loss: An In Vitro and a Randomized Clinical Study

    Pharmaceuticals (Basel, Switzerland)

More on Stem cell differentiation

Autophagy

upin mice1upin rats1

2 studies
  1. Simvastatin activates autophagy in mice (Fasting-phase administration in wild-type mice).

    “fasting-phase simvastatin activated SREBP-2-dependent autophagy”

    AnimalsFasting-phase administration in wild-type miceliver

    TLR4 modulates simvastatin's impact on HDL cholesterol and glycemic control

    Frontiers in pharmacology

  2. Simvastatin activates autophagy in rats (AlCl3-induced rat model; free and nanocarrier forms).

    “Simva and its nanocarrier enhanced autophagy by upregulating p-AMPK, p-ULK1, and LC3-II”

    AnimalsAlCl3-induced rat model; free and nanocarrier forms10 mg/kg28 daysmales

    Nanocarrier-enhanced simvastatin modulates AMPK-ULK1 pathway and oxidative stress in Alzheimer's disease model

    European journal of pharmacology

More on Autophagy

Oxidative phosphorylation

upin cells1downin humans1

2 studies
  1. Simvastatin impairs oxidative phosphorylation in statin-myalgic and non-symptomatic groups compared with controls.

    “Mitochondrial complex II-linked respiration was reduced in the statin-myalgic and -NS groups compared with the control group.”

    Human trialin statin-myalgic and non-symptomatic groups compared with controlsskeletal muscle

    Statin Treatment Decreases Mitochondrial Respiration But Muscle Coenzyme Q10 Levels Are Unaltered: The LIFESTAT Study

    The Journal of clinical endocrinology and metabolism

  2. Simvastatin improves oxidative phosphorylation in doxorubicin and old VSMCs.

    “Simvastatin 0.1 μM reduces the senescence-associated secretory phenotype (SASP) and ROS production and improves mitochondrial respiration in doxorubicin and old VSMCs.”

    Cellsin doxorubicin and old VSMCs0.1 μM

    Simvastatin ameliorates senescence-induced mitochondrial dysfunction in vascular smooth muscle cells

    Atherosclerosis

More on Oxidative phosphorylation

Senescence-associated secretory phenotype (SASP)

downin cells1downin human cells1

2 studies
  1. Simvastatin inhibits senescence-associated secretory phenotype (SASP) in doxorubicin and old VSMCs.

    “Simvastatin 0.1 μM reduces the senescence-associated secretory phenotype (SASP) and ROS production and improves mitochondrial respiration in doxorubicin and old VSMCs.”

    Cellsin doxorubicin and old VSMCs0.1 μM

    Simvastatin ameliorates senescence-induced mitochondrial dysfunction in vascular smooth muscle cells

    Atherosclerosis

  2. Simvastatin prevents senescence-associated secretory phenotype (SASP) in human cells (PMS iNSCs).

    “Chemical targeting of HMG-CoA reductase using the cholesterol-lowering drug simvastatin (SV) prevented SASP release and resulting neurotoxicity.”

    CellsPMS iNSCs

    Increased Cholesterol Synthesis Drives Neurotoxicity in Patient Stem Cell-Derived Model of Multiple Sclerosis

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

More on Senescence-associated secretory phenotype (SASP)

Cellular senescence

downin human cells2

2 studies
  1. Simvastatin decreases cellular senescence in TNF-alpha-treated cells.

    “with a corresponding reduction in TNF-alpha-induced senescence”

    Cellsin TNF-alpha-treated cellshuman umbilical vein endothelial cell

    Tumor Necrosis Factor-alpha (TNF-α) Enhances miR-155-Mediated Endothelial Senescence by Targeting Sirtuin1 (SIRT1)

    Medical science monitor : international medical journal of experimental and clinical research

  2. Simvastatin decreases cellular senescence in human cells (cotreatment with cigarette smoke extract).

    “Both simvastatin and rosuvastatin downregulated OS-induced p38MAPK activation, senescence, and SASP”

    Cellscotreatment with cigarette smoke extractfetal membranes100 and 200 ng/mLn = 8

    Regulation of p38 mitogen-activated kinase-mediated fetal membrane senescence by statins

    American journal of reproductive immunology (New York, N.Y. : 1989)

More on Cellular senescence

Postoperative pain

no changein humans1no changein reviews1

1 study
  1. Simvastatin showed no clear effect on postoperative pain in humans (mandibular third molar extraction).

    “The SIM gel demonstrated an excellent safety profile, with no significant differences regarding postoperative pain or swelling compared to the placebo.”

    Human trialmandibular third molar extractiongel combined with a collagen sponge carrieralveolar bone1.2%12 weeksn = 38

    Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial

    Clinical oral investigations

  2. Simvastatin showed no clear effect on postoperative pain (4.38 ± 1.85 vs 4.58 ± 2.30 at 24 h).

    “No statistically significant differences in postoperative pain or swelling were observed between the Test (SIM) and Control (Placebo) groups at any of the assessed time points, which included immediate assessment (0 h) and specific intervals up to 7 days postoperatively (see Tables and ).”

    Review12 weeksn = 40

    Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial

    Clinical oral investigations

Bone width preservation

no changein humans1no changein reviews1

1 study
  1. Simvastatin showed no clear effect on bone width preservation in humans (mandibular third molar extraction) (p > 0.05).

    “No statistically significant difference was observed in exploratory bone width preservation (p > 0.05).”

    Human trialmandibular third molar extractiongel combined with a collagen sponge carrieralveolar bone1.2%12 weeksn = 38

    Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial

    Clinical oral investigations

  2. Simvastatin showed no clear effect on bone width preservation.

    “For horizontal ridge width changes, the between-group mean differences were small and not statistically significant, with all 95% confidence intervals crossing zero.”

    Review12 weeksn = 38

    Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial

    Clinical oral investigations

Vertical alveolar bone height preservation

upin humans1

1 study
  1. Simvastatin improves vertical alveolar bone height preservation in humans (-1.58 mm, 95% CI: -3.26 to -0.73 mm).

    “Dimensional changes in bone height (ΔH) were analyzed individually, revealing a mean gain in bone height (− 0.30 ± 1.79 mm) in sockets treated with 1.2% topical SIM gel (Test Group, n = 19), compared to a mean reduction in height (1.28 ± 1.50 mm loss) observed in the Control Group (n = 19).”

    Human trial12 weeksn = 38

    Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial

    Clinical oral investigations

  2. Simvastatin improves vertical alveolar bone height preservation in humans (mandibular third molar extraction) (−0.30 ± 1.79 mm vs 1.28 ± 1.50 mm loss, p = 0.006).

    “The Test Group (SIM) showed significantly greater vertical bone preservation, with a mean change in height of − 0.30 ± 1.79 mm”

    Human trialmandibular third molar extractiongel combined with a collagen sponge carrieralveolar bone1.2%12 weeksn = 38

    Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial

    Clinical oral investigations

Peri-implant crestal bone loss

downin humans1

1 study
  1. Simvastatin decreases peri-implant crestal bone loss (combined with PRF at extraction site before immediate implant placement) (0.421 ± 0.023 mm vs 0.630 ± 0.048 mm).

    “At the 0–3 month interval, both the PRF-Bone and PRF-SIM groups exhibited significantly lower mean crestal bone loss than the PRF group (p < 0.0001), with mean changes of 0.424 ± 0.043 mm, 0.421 ± 0.023 mm, and 0.630 ± 0.048 mm, respectively.”

    Human trialcombined with PRF at extraction site before immediate implant placement12 monthsmalesn = 24

    Simvastatin Enhances Stem Cell Osteogenesis and Reduces Peri-Implant Bone Loss: An In Vitro and a Randomized Clinical Study

    Pharmaceuticals (Basel, Switzerland)

  2. Simvastatin decreases peri-implant crestal bone loss in humans (immediate-implant cases) (p < 0.001).

    “Radiographic analysis revealed significantly reduced crestal bone loss (p < 0.001) in the PRF-SIM and PRF-Bone groups compared to PRF alone”

    Human trialimmediate-implant cases12 monthsn = 24

    Simvastatin Enhances Stem Cell Osteogenesis and Reduces Peri-Implant Bone Loss: An In Vitro and a Randomized Clinical Study

    Pharmaceuticals (Basel, Switzerland)

Pulpotomy success rate

no changein humans1

1 study
  1. Simvastatin showed no clear effect on pulpotomy success rate in cariously exposed permanent mandibular molars with symptomatic irreversible pulpitis (92.5% vs 96.2%).

    “No significant difference in success rates was found between the SMV-αTCP (92.5%) and MTA (96.2%) groups (p > 0.05).”

    Human trialin cariously exposed permanent mandibular molars with symptomatic irreversible pulpitis12 monthsn = 60

    Effect of Simvastatin on Success of Pulpotomy in Carious Permanent Molars With Symptomatic Irreversible Pulpitis: A Randomised Controlled Trial

    Australian endodontic journal : the journal of the Australian Society of Endodontology Inc

All 143

What is simvastatin linked with?

21

Studies link simvastatin with 21 measures, among them cognitive function, cholelithiasis and hyperglycemic event reporting.

Cognitive function

upin humans2

2 studies
  1. Simvastatin is associated with cognitive function in humans (Alzheimer's disease patients at baseline) (0.53 points higher MMSE (se 0.23, p = 0.021)).

    “Simvastatin users had 0.53 points higher MMSE on average at baseline compared to non-users of statins (se 0.23, p = 0.021).”

    HumansAlzheimer's disease patients at baselinen = 3,074

    Statins, cholesterol and cognition at the time of Alzheimer's disease diagnosis: A cross-sectional study from the Swedish registry for cognitive/dementia disorders

    Journal of Alzheimer's disease reports

  2. Simvastatin is associated with cognitive function in humans (compared with atorvastatin users) (1.01 more MMSE points after 3 years (95% CI 0.06;1.97)).

    “Simvastatin users showed 1.01 more MMSE points (95% CI: 0.06;1.97) after 3 years compared to atorvastatin users.”

    Humanscompared with atorvastatin users3 years

    Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study

    Alzheimer's research & therapy

Cholelithiasis

downin humans1

1 study
  1. Simvastatin is associated with cholelithiasis in humans (Genetic correlation of medication-use liability) (rg = −0.277; p = 1.54 × 10−4).

    “CL showed inverse genetic correlations with SIM (rg = –0.277, p = 1.54 × 10–4)”

    HumansGenetic correlation of medication-use liability

    Shared genetic architecture and mendelian randomisation between simvastatin-related medication use and cholelithiasis: a multi-method GWAS-based analysis

    Archives of medical science : AMS

More on Cholelithiasis

Hyperglycemic event reporting

upin humans1

1 study
  1. Simvastatin is associated with hyperglycemic event reporting in humans (FAERS pharmacovigilance analysis in patients without diabetes) (Reporting odds ratio 1.22; 95% CI 1.13–1.32).

    “simvastatin (ROR: 1.22; 95% CI: 1.13-1.32)”

    HumansFAERS pharmacovigilance analysis in patients without diabetes

    Risk of hyperglycemia with different statins by type and dose: a network meta-analysis and real-world pharmacovigilance study

    Frontiers in pharmacology

Amnesia

upin humans1

1 study
  1. Simvastatin is linked with a higher risk of amnesia in humans (ROR = 4.94, 95% CI: 4.55-5.35).

    “simvastatin (n = 600, ROR = 4.94, 95% CI: 4.55-5.35, P < 0.001)”

    Humansn = 600

    Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database

    Frontiers in pharmacology

More on Amnesia

Type 2 diabetes

upin humans1HR 1.15

1 study
  1. Simvastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (HR 1.15, 95% CI 1.06-1.20).

    “simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”

    Humansin patients with established ASCVD on moderate-intensity statin therapy

    Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort

    Frontiers in cardiovascular medicine

More on Type 2 diabetes

BKα channel activity

mixedin human cells1

1 study
  1. Simvastatin is associated with BKα channel activity in human cells (Calcium-dependent modulation).

    “Simvastatin directly modulates BKα channels in a calcium-dependent manner.”

    CellsCalcium-dependent modulationHEK293T cell

    Differential modulation of BK channels by simvastatin: Critical role of the auxiliary β4 subunit

    British journal of pharmacology

CCL20, NFKBIA, and ICAM1

mixedin silico1

1 study
  1. Simvastatin is associated with CCL20, NFKBIA, and ICAM1 in silico (small-molecule drug prediction and molecular docking).

    “Simvastatin: Linked to CCL20, NFKBIA, and ICAM1.”

    In silicosmall-molecule drug prediction and molecular dockinggastric epithelial cell

    Integrated transcriptomics and molecular docking identify hub genes and statin regulators in Helicobacter pylori-associated gastric mucosal pathogenesis

    Frontiers in cellular and infection microbiology

Rhabdomyolysis

upin humans1

1 study
  1. Simvastatin is associated with rhabdomyolysis in humans (concurrent hydrochlorothiazide and empagliflozin) (creatine kinase 12,165 U/L).

    “who developed severe rhabdomyolysis, acute kidney injury, and transaminitis while taking simvastatin, hydrochlorothiazide, and empagliflozin”

    Humansconcurrent hydrochlorothiazide and empagliflozinfemales

    Severe Rhabdomyolysis in an Elderly Patient With Diabetes and Vascular Disease: Interplay of Statin Therapy, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibition, and Thiazide-Induced Hypokalemia

    Cureus

More on Rhabdomyolysis

LEPR

no changein silico1

1 study
  1. Simvastatin is associated with LEPR in silico (predicted by molecular docking).

    “simvastatin could stably bind to LEPR”

    In silicopredicted by molecular docking

    Identification and analysis of immune aging related biomarkers in cartilage and meniscus tissues of osteoarthritis

    American journal of clinical and experimental immunology

More on LEPR

Liver function derangement

upin humans1

1 study
  1. Simvastatin is associated with liver function derangement in humans (rechallenge after atorvastatin discontinuation).

    “a rechallenge with simvastatin, resulting in recurrent liver function derangement.”

    Humansrechallenge after atorvastatin discontinuationliverfemales

    Atorvastatin unveiling primary biliary cholangitis and autoimmune hepatitis overlap syndrome in an older adult: A case report

    Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

Cardiocerebrovascular events

downin humans1

1 study
  1. Simvastatin lowers the risk of cardiocerebrovascular events in humans (carotid atherosclerotic plaque).

    “Moreover, the overall incidence of acute cardiocerebrovascular events was lower in the observation group than in the control group.”

    Human trialcarotid atherosclerotic plaquetablet20 mg/dayn = 65

    Efficacy of simvastatin on carotid atherosclerotic plaque and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients

    Experimental and therapeutic medicine

More on Cardiocerebrovascular events

All 21

Has simvastatin been tested in people?

69 of 356 about aging

Yes: 38 trials and 49 observational studies in people have been published, and 342 trials are registered.

Approved

  • FDA Zocor

    Dec 23, 1991Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia, Coronary Heart Disease, Heterozygous Familial Hypercholesterolemia, dysbetalipoproteinemia, Myocardial Infarction, Stroke, Hyperlipidemia, primary hyperlipidemia, non-fatal myocardial infarction, myocardial infarction and stroke

  • FDA Simvastatin

    Oct 9, 2007Discontinued

  • FDA Flolipid

    Apr 21, 2016

Repurposing

40 of 162

Every condition in trials

  • Hyperlipidemias

    Phase 4Completed19 trials

  • Precursor cell lymphoblastic leukemia lymphoma

    Phase 4Status unknown1 trial

  • Respiratory distress syndrome

    Phase 4Status unknown1 trial

  • Hyperlipoproteinemia type II

    Phase 3Results posted7 trials

  • Cholesterol

    Phase 3Completed1 trial

  • Liver Cirrhoses

    Phase 2/3Completed2 trials

All 18

Stopped

  • NCT04021498TerminatedPancreatitis

    Slow recruitment

  • NCT02096588TerminatedBreast neoplasm

    The Principal Investigator left Johns Hopkins

  • NCT00528580TerminatedInfection

    Inadequate recruitment

  • NCT00718328TerminatedCerebral hemorrhage

    Poor recruitment, trial terminated

  • NCT00575965TerminatedWaldenström macroglobulinemia

    Slow accrual led to early study termination.

  • NCT01654562TerminatedChoroideremia

    The study has been terminated due to limited participant enrollment.

All 7

Who is developing simvastatin?

3 companies: Organon, Tanabe Pharma and AstraZeneca.

Companies
  • OrganonPhase 4atherosclerosis, hypercholesterolemia
  • Tanabe PharmaPhase 1
  • AstraZenecaPhase 1non-small cell lung cancer

Trial sponsors

Funding

4 grants since 2016

National Institute of Diabetes and Digestive and Kidney Diseases$3.9MNational Institute for Health Research£4.4MJapan Society for the Promotion of Science¥4.4M

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 7Jan 2026: 12Feb 2026: 26Mar 2026: 12Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 2Aug 2026: 3Sep 2026: 1Oct 2026: 5Nov 2026: 271 papers in 12 months
Frontiers in Pharmacology

Genetic study links protein to spinal narrowing in people

Genetic analyses using two European-ancestry datasets linked higher genetically predicted levels of placental alkaline phosphatase, a protein, to greater risk of spinal…Genetic analyses using two European-ancestry datasets linked higher genetically predicted levels of placental alkaline phosphatase, a protein, to greater risk of spinal canal narrowing.

Mendelian randomizationInterventions

See all 215 papers on simvastatin